CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 82 enrolled
Drug / intervention
Ropinirole Prolonged releasedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00986245
NCT00986245Phase 4Completed
CompareCT.gov

An Open-label, Multi-center, Crossover Study to Compare the Effect of Once-daily Ropinirole PR and Twice-daily Ropinirole PR in Patients With Parkinson Disease

Seoul National University Hospital·interventional·Posted Sep 29, 2009·Updated Sep 9, 2013

In Brief

A Phase 4 clinical trial evaluating Ropinirole Prolonged release for Parkinson Disease. Completed, enrolled 82 participants across 2 sites.

Detailed Summary

1. In order to compare the benefit, side effects, and patient preference of Ropinirole prolonged release when used in once-daily or twice-daily dosing 2. In order to estimate the conversion rate of dopamine agonists into Ropinirole prolonged release

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesSouth Korea
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 29, 2009
Enrollment StartSep 1, 2009
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.8 years ago

Interventions

Ropinirole Prolonged releasedrug

Change Ropinirole immediate release or Pramipexole immediate release to Ropinirole prolonged release (PR) once-daily or twice-daily